SCHEMBL28854014

SCHEMBL28854014

Cc1ccc([N+](=O)[O-])cc1CCCC(N)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.49
TSHR P16473 2/20 0.49
ALDH1A1 P00352 8/20 0.49
TDP1 Q9NUW8 4/20 0.49
LMNA P02545 2/20 0.46
KAT2B Q92831 1/20 0.44
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.43
PDE2A O00408 1/20 0.42
PDE5A O76074 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
PDE4A P27815 1/20 0.42
BLM P54132 1/20 0.42
PDE1B Q01064 1/20 0.42
PMP22 Q01453 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4D Q08499 1/20 0.42
PDE7A Q13946 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4658055 0.96 CYP3A4 (0.47) CYP3A4TSHRALDH1A1TDP1LMNA
SCHEMBL6405854 0.93 ALDH1A1 (0.50) CYP3A4TSHRALDH1A1TDP1LMNA
SCHEMBL5106226 0.84 LMNA (0.46) CYP3A4TSHRALDH1A1TDP1LMNA
SCHEMBL28040672 0.83 ALDH1A1 (0.53) CYP3A4TSHRALDH1A1TDP1LMNA
SCHEMBL28290292 0.82 NPSR1 (0.56) CYP3A4TSHRALDH1A1TDP1LMNA
SCHEMBL903286 0.82 TDP1 (0.48) ALDH1A1TDP1MAPTCYP1A2KMT2A
SCHEMBL28744999 0.81 ALDH1A1 (0.55) CYP3A4TSHRALDH1A1TDP1KAT2B
SCHEMBL12527468 0.81 ALDH1A1 (0.49) CYP3A4TSHRALDH1A1TDP1MAPT
SCHEMBL16975448 0.80 ALDH1A1 (0.56) CYP3A4TSHRALDH1A1TDP1LMNA
SCHEMBL10340437 0.78 ALDH1A1 (0.58) CYP3A4TSHRALDH1A1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107531645-A The inhibitor of gangrenosum acne apoptosis 催化剂治疗私人有限公司 2018-01-02 CN disclosed